Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma

22 Oct 2022

Abstract excerpt

BACKGROUND: Temozolomide (TMZ) resistance has become an important obstacle affecting its therapeutic benefits. O6-methylguanine DNA methyltransferase (MGMT) is primarily responsible for the TMZ resistance in Glioblastoma multiforme (GBM) patients. In addition, active DNA damage repair pathways can also lead to TMZ resistance. Here, we reported a novel small-molecule inhibitor EPIC-0412 that improved the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36272139
DOI: 10.1093/neuonc/noac242

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastomaPMID 36272139Read ↗

EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMTSemantic proximity Read ↗

Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma CellsSemantic proximity Read ↗

Advances in epigenetic glioblastoma therapySemantic proximity Read ↗

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read ↗

PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomideSemantic proximity Read ↗

Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cellsSemantic proximity Read ↗

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastomaSemantic proximity Read ↗

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in GlioblastomaSemantic proximity Read ↗

Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping ReviewSemantic proximity Read ↗

Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for GlioblastomaSemantic proximity Read ↗

High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/β-catenin/MGMT pathwaySemantic proximity Read ↗

Functional Genomic Screens Reveal RBBP4 as a Key Regulator of Cell Cycle Progression in TMZ-Resistant GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.